The present invention provides a method for measuring growth hormone level in a human child, including a method of assessing pituitary-related growth hormone deficiency in a human child as a stand-alone test. The method includes the steps of oral administration of an effective amount of macimorelin to the child, collecting from the child two or three post-administration blood samples within a range of about 60 minutes after administration, and determining the level of growth hormone in the samples. The method can be used for diagnosing pituitary-related growth hormone deficiency in a child when the peak level of determined growth hormone in the samples is below a cut-off value.

Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHM. Also described is a method of treating growth hormone (GH) deficiency (MD) in children with a functional hypothalamic-pituitary GH axis.

The present invention relates to a method for measuring growth hormone level in a human child, including a method of assessing pituitary-related growth hormone deficiency in a human child as a stand-alone test. The method comprises oral administration of an effective amount of macimorelin to the child, collecting from the child two or up to four post-administration blood samples within a range of about 90 minutes after administration, and determining the level of growth hormone in the samples. The method can be used for diagnosing pituitary-related growth hormone deficiency in a child when the peak level of determined growth hormone in the samples is below a cut-off value.

The present disclosure provides a method for identifying a human growth hormone proteoform (hGHP) pattern biomarker. The method includes: collecting an hGH-secreting pituitary adenoma tissue sample and a normal pituitary tissue sample, and extracting tissue proteins, separately; conducting two-dimensional gel electrophoresis (2DGE), western blotting, and Coomassie brilliant blue (CBB) staining, and scanning visualized polyvinylidene fluoride (PVDF) membranes and 2D gels to obtain digital images; subjecting a corresponding protein in 2D gel spot to protein digestion with trypsin and purification, and conducting mass spectrometry identification and bioinformatics analysis to identify a GHP biomarker profile; and in combination with bioinformatics, using quantitative phosphoproteomics, quantitative ubiquitinomics, and quantitative acetylomics to identify post-translational modifications (PTMs) and splicing variations in GHP. The present disclosure can identify a change pattern of GHP between a GH-secreting pituitary adenoma tissue and a normal pituitary tissue. In total, 46 GHPs are identified in the GH-secreting pituitary adenoma tissue, and only 35 GHPs are identified in the normal pituitary tissue. Therefore, 11 GHPs are only present in the GH-secreting pituitary adenoma tissue.

Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.

Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.

Methods, systems, and kits for detection, diagnosis, monitoring, and/or treatment of viral infections such as represented by the COVID-19 disease are described. The methods, systems, and kits are capable of detection of salivary biomarkers which correlate with, and are indicative of, COVID-19 in a subject. Detection of the biomarkers in a saliva sample provides opportunities for a COVID-19 or other viral detection assay which is non-invasive, produces rapid results, and can be implemented in the field on a wide geographic basis for individualized screening or mass screenings for COVID-19 or other viral infections.

Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.

The present invention discloses a competitive lateral flow immunoassay for detection of recombinant bovine somatotropin (rbSt) in bovine milk or a milk product or extract thereof from lactating dairy cows treated/injected with rbSt. The rbSt (analyte) in milk or its derivatives, is added to a sample pad. The rbSt mouse or rat monoclonal antibody (primary antibody) is complexed to gold nano-particles and dried down on the conjugate pad. This complex (gold conjugated to monoclonal anti-rbSt) then flows to the test and control lines by capillary action through their respective channels, as a result of the osmolarity of the wicking pad. A solution of rbSt-BSA (Bovine Serum Albumin) is striped/bound to the test line. As the conjugate is rehydrated by the sample and flows down the strip, rbSt, if present in the test sample (milk), competes with rbS-BSA at the test line for binding to the gold labeled rbSt monoclonal primary antibody. If rbSt is present in the sample, the test line signal will be lighter than if there was no rbSt. The test line signal is inversely proportional to the rbSt concentration in the milk sample. The control line contains a second antibody (IgG) directed against the primary monoclonal antibody bound to the gold particle. The test line and control lines are analyzed by a reader containing a photodiode (leelu reader.)

A carbon nanofiber-based label free electrochemical immunosensor for sensitive detection of proteins in a fluid is described. The immunosensor as disclosed is a modified carbon nano-fiber screen printed electrode (CNF-SPE) wherein the electrode is modified with a carboxyphenyl film and then activated by EDC/NHS. Further, a monolayer of 4-aminophenylboronic acid coating was then fabricated onto the electrode to allow orientation of antibody via bonding of boronic acid-saccharide of oligosaccharide moiety located on the Fc region of antibody. The modified electrode is then used for the detection of a hormone such as rbST in a fluid with a detection limit of 1 pg/ml.